Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017 Ovarian Cancer - Treatment Landscape & Competitive | Page 3

Ovarian Cancer - Treatment Landscape &
Competitive Analysis, 2017
This report provides the insights of the marketed drugs for the Ovarian Cancer which includes the Targeted
Therapy and Chemotherapy. These days’ companies are focusing on the Targeted Therapy for cancer. Many
big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib
of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years.
All are in preregistration stage. Along with the Targeted Therapy, this report also provides the landscape of
Chemotherapy available for the Ovarian Cancer.
This report also covers the comparison of the Targeted Therapy and Chemotherapy which provides the
insights for the marketed drugs. Analysis of the marketed drugs provides the understanding of cost of
treatment, therapeutic class, patent expiry and sales data of the drugs.
This report covers the treatment landscape which provides the treatment options by different stages of the
ovarian cancer. Currently the treatment is divided into the Targeted therapy and Chemotherapy. There are
two products under Targeted therapy and seven products under Chemotherapy.
Inquire more before buying this report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=894782.